Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

David Orchard-Webb, PhD, MTS: Scientist II – DrugDiscovery @LPBI Group, Cancer Indication

Roles @LPBI Group

A. Expert, Author, Writer on the following declared 12 domains of interest and expertise

1. Anticancer Resistance
2. Autoimmune Inflammatory Diseases
3. Biomarkers & Medical Diagnostics
4. Cancer and Therapeutics
5. CANCER BIOLOGY & Innovations in Cancer Therapy
6. Cancer Prevention: Research & Programs
7. Cancer Screening
8. Childhood cancer
9. Immunotherapy
10. Next Generation Sequencing (NGS)
11. Clinical Trials and IRB related issues
12. Pharmaceutical R&D Investment

B.  MTS: Scientist II – DrugDiscovery @LPBI Group, Cancer Indications

David Orchard-Webb, PhD

Montréal, Canada

d.orchard-webb@bath.edu

+1 438 823 0338

https://davidorchardwebb.wordpress.com/

Languages: English (native), French (professional working proficiency)

Email:	biosci.resources@gmail.com
Website:	https://biosci-rc.com/
Phone:	+1 438 823 0338

Goal: to facilitate the research and development of therapeutics especially in the biologics sector.

Specialties: innovation, analytics, cancer biology, pancreatic disorders, biologics, process development, molecular and cellular biology.

 

Education

 

November 2007 – 2011 University of Leeds – PhD – The cancer cell biology of the integral membrane protein CUB Domain Containing Protein 1 (CDCP1). Supervised by Professor Eric G. Blair and Dr. Graham P. Cook.

 

October 2003 – June 2007 University of Bath – Master of Molecular & Cellular Biology (MCB)  Degree Classification: 2(i)

 

Work Experience

 

November 2016 – Present: Research Assistant – Athla LLC/ HealthLabs/ MedStar Institutes for Innovation at MedStar Health in Washington (Remote)

 

“Smart medical data” bioinformatic project coordinated by Michael Gillam, MD. I assist Dr. Gillam with writing papers based on anonymous medical statistics from 6 hospitals in the Washington DC area.

 

May 2016 – Present: Research Assistant – McGill University- Department of Bioengineering

 

I assist professor Kamen with grant proposals and paper editing. In addition I am involved in BSL-2 bioengineering laboratory based vaccine characterization and cell culture development projects.

 

March 2016 – Present: MTS: Scientist II – DrugDiscovery @LPBI Group

 

DrugDiscovery @LPBI Group is a biotechnology pre-startup. Current responsibilities include establishing an IP position and developing an R&D program focused on the innovation of novel nano-oncolytic-immunotherapeutic technologies for cancer patients with high unmet medical need.

 

https://pharmaceuticalintelligence.com/drugdiscovery-lpbi-group/

 

January 2015 – present: Independent Consultant – Montréal

 

Bioscience Resources Consulting: Personal consulting website which provides biotech updates with a focus on pancreatic cancer. Scientific writing services are provided. Whitepapers available. Bioscience enquiries welcome.

 

https://biosci-rc.com/

 

Propel(x): Participated in evaluating an investment opportunity on the Propel(x) platform – addressed investor questions and shared insights on the fundraising company’s breakthrough science & technology, market size, and competitive landscape. Propel(x) is an angel investment platform exclusively focused on funding ‘deep technology’ startups – companies founded on a scientific discovery or meaningful engineering innovation.

 

VIE-TECH Consultants: I delivered a report concerning discovery and preclinical biologic development.

 

 

December 2013 – December 2014: Visiting Research Fellow: University of Leeds.

 

Achievements included the publishing of a first author research paper and a review article.

 

 

January 2012 – November 2013: Research Fellow: University of Leeds. Project title: Development of novel oncolytic adenoviruses for pancreatic cancer therapy.

 

Achievements included:

 

• Managed cell culture facility. Received and shipped cell lines according to MTAs.
• Constructed oncolytic adenovirus vectors that target pancreatic cancer.
• Monitored adenovirus infections via hexon flow cytometry assay.
• Developed an organotypic pancreatic cancer cell culture model, which involved teamwork and a high pressure environment.
• Developed, wrote and maintained protocols and SOPs
• Supervised, organised and trained masters and undergraduates in the Blair lab.
• Taught and examined undergraduates – The cell cycle – interactive seminar course.
• Liaised with external suppliers such as Starlab.
• Presented findings at national and international meetings.

 

April 2011 – December 2011: Research Fellow: University of Leeds. Project title: Defining the role of polyomavirus-encoded oncoproteins in the immune response to Merkel cell carcinoma.

 

• Identified upregulated and down-regulated cell surface proteins from an NGS dataset of a Merkel cell carcinoma that contained an integrated Merkel Cell Polyomavirus.
• Cloned a novel variant of the Merkel Cell Polyomavirus large T identified in the tumour material.
• Demonstrated that the large T variant had an altered cellular localisation compared to that found in the non-integrated virus by immunofluorescence microscopy.
• Concluded that truncated large T did not alter the cell surface expression of CD200 in primary keratinocyte cells by flow cytometry.

 

November 2007- February 2011: PhD: University of Leeds. The cancer cell biology of the integral membrane protein CUB Domain Containing Protein 1 (CDCP1). Supervised by Professor Eric G. Blair and Dr. Graham P. Cook.

 

I was employed as a research fellow with laboratory management responsibilities. In addition I undertook a PhD exploring the role of the protein CDCP1 in cancer. This work included published cellular functional assays resulting from CDCP1 knockdown by siRNA [3].

 

• Led team of 5 PhD candidates in the BBSRC Biotechnology Young Entrepreneurs Scheme (Biotechnology YES) competition. We were awarded best initial pitch.
• Successful completion of thesis and defence
• Presented my findings at national and European conferences

 

4^th July 2007 – 31^st August 2007: Research Assistant: University of Bath.

 

I developed a cell culture system for studying neuromuscular junctions (NMJs) using established cell lines under the supervision of Dr. Vasanta Subramanian.

 

August 2005 – August 2006: Sabbatical Scholar: Webb-Waring Institute for Cancer, Aging, and Antioxidant Research. Affiliated with the University of Colorado, Denver, Colorado U.S.A.

 

I finished in the top 10% of my first year undergraduate and therefore qualified to undertake the undergraduate Masters course which involved a year in industry/research laboratory.

 

I developed a new model of epithelial to mesenchymal transition (EMT). This model was used to determine a role for xanthine oxidoreductase in cancer cells.

 

 

Volunteer Experience & Causes

 

January 2014 – February 2014: English as a Second Language Teaching Assistant: Maison de l’amitié, Montréal

 

• I prepared and aided in the teaching of a weekly 3 hour English class for new Canadian immigrants.

 

Awards

 

July 2012: Yorkshire Cancer Research Travel Grant to give talk at the international DNA Tumour Virus Meeting, Montreal, Canada.

 

July 2010: Yorkshire Cancer Research Travel Grant to present a poster at the 21st meeting of the European Association for Cancer Research, Oslo, Norway.

 

 

Publications

 

1. Orchard-Webb D. 2016. Progress Toward Commercial Scale and Efficiency in Cell Therapy Bioprocessing. BioProcess International. October Supplement. http://www.bioprocessintl.com/manufacturing/cell-therapies/manufacturing-cell-therapies-commercial-scale-efficiency/

 

2. Orchard-Webb D. 2015. Future Directions in Pancreatic Cancer Therapy. JOP. Journal of the Pancreas 16:249-255.

 

3. Orchard-Webb D.J., Lee T.C., Cook G.P., Blair G.E. 2014. CUB Domain Containing Protein 1 (CDCP1) modulates adhesion and motility in colon cancer cells. BMC Cancer. 14:754.

 

4. Orchard-Webb D; Fox N; Elghazawy RM; Speirs V; Smith AM; Lodge JPA; Melcher AA; Verbeke CS; Blair GE. 2012. Development of a Chimaeric Oncolytic Adenovirus Vector for Pancreatic Cancer Biotherapy. Journal of pathology. 228: S18-S18.

 

5. Elghazawy RM; Fox N; Orchard-Webb D; Speirs V; Smith AM; Lodge JPA; Verbeke CS; Blair GE. 2012. An Ex-Vivo Model of Human Pancreatic Cancer. Journal of pathology. 228: S19-S19.

 

6. Orchard-Webb, D. 2011. The cancer cell biology of the integral membrane protein CUB domain containing protein 1 (CDCP1). University of Leeds. Thesis.

 

7. Orchard-Webb, D. J., Cook, G. P., and Blair, G. E. 2010. Poster 482: Characterising the role of the metastasis associated cell surface glycoprotein CDCP1 in cancer cell lines – possible roles in cell adhesion and survival. EJC Supplements 8: 123.

 

8. Fini, M.A., Orchard-Webb, D., Kosmider, B., Amon, J.D., Kelland, R., Shibao, G., and Wright, R.M. 2008. Migratory Activity of Human Breast Cancer Cells is Modulated by Differential Expression of Xanthine Oxidoreductase. J. Cell. Biochem. 105: 1008-1026.